RxDoctor Payments Data

Thomas Coppola, DO

Gastroenterology · Louisville, KYNPI 1215297437

Payments from drug & device makers

$1,450in general payments, 2019–2025

Across 66 payments — averaging $21.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$394
  • Janssen Scientific Affairs, LLC$232
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$223
  • Takeda Pharmaceuticals U.S.A., Inc.$128
  • Bristol Myers Squibb$118
  • Johnson & Johnson$63
  • plus $293 from 11 others

What the payments were for

  • Consulting fees$151%
  • Food & beverage$1,43599%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,450 in reported general payments places this provider in the 30th percentile of 207 gastroenterology providers in Kentucky.

See all gastroenterology providers in Kentucky

Medicare billing

Part B allowed, 2024
$115,190
Medicare patients
530
Services billed
899

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab17$447,401
XifaxanRifaximin24$95,796
LinzessLinaclotide40$45,933
Mesalamine21$8,404
MotegrityPrucalopride Succinate13$7,311
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates74$5,311
Pantoprazole Sodium449$5,151
Ursodiol16$3,513
NexiumEsomeprazole Magnesium11$2,977
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg77$1,668
Omeprazole197$1,645
Lubiprostone13$1,553
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl104$1,536
Esomeprazole Magnesium42$1,258
Colestipol Hcl11$1,186

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$63$447,40117 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$223$95,79624 claims
AbbVieLinzess$394$45,93340 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$128$7,31113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 207 gastroenterology providers in Kentucky.

Other gastroenterology in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →